Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

D-Wave Quantum Inc.

organization80% conf.·synced Aug 13, 2026

Quantum computing company specializing in annealing quantum computers and Quantum Compute as a Service

54
sourced metrics
204
relationships
20
stated objectives
2
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Share
179.30price_to_sales_ratio
May 26, 2026source
Cash
588USD
May 19, 2026source
Backlog
33.4USD
May 19, 2026source
Gross Margin Gaap
55.8percent
Jan 22, 2026⚠ sources conflictsource
Gross Margin Non Gaap
67.2percent
Jan 22, 2026⚠ sources conflictsource
Lincoln Park Equity Line Remaining
49.9million_USD
Jan 22, 2026source
Bookings
7.4million_USD
Jan 22, 2026⚠ sources conflictsource
Adjusted Ebitda Loss
13.8million_USD
Jan 22, 2026⚠ sources conflictsource
Atm Program Remaining
79.1million_USD
Jan 22, 2026source
Eps
-0.51USD
Jan 22, 2026⚠ sources conflictsource
Total Customers
132customers
Jan 22, 2026⚠ sources conflictsource
Commercial Customers
76customers
Jan 22, 2026⚠ sources conflictsource
Commercial Revenue Decrease
0.2million_USD
Jan 22, 2026source
Forbes Global 2000 Customers
27customers
Jan 22, 2026⚠ sources conflictsource
Research Revenue Increase
0.6million_USD
Jan 22, 2026source
Qcaas Revenue
5.1million_USD
Jan 22, 2026⚠ sources conflictsource
Professional Services Revenue
0.3million_USD
Jan 22, 2026⚠ sources conflictsource
Patent Count
240patents
Jan 22, 2026⚠ sources conflictsource

Stated objectives

Q1 2025 revenue expected to exceed $10M

source
target: >10M USD by 2025-03-31 00:00:00stated

Commercial rollout of Advantage 2 system planned for 2025

source
by 2025-12-31 00:00:00stated

Reach profitability as first pure play quantum company

source
target: positive net income stated

Complete testing of Advantage3 prototype chip

source
by 2025-12-31 00:00:00stated

Demonstrate first gate model fluxonium qubit system with scalable cryogenic control

source
by 2026-12-31 00:00:00stated

Deploy scaled error-corrected gate model quantum system

source
stated

Scale Advantage3 to 100,000 qubits with multi-chip processor fabric

source
target: 100000 qubits stated

Deploy Advantage2 system in Lombardy, Italy for Q-Alliance

source
by 2026-12-31 00:00:00stated

Achieve path to profitability with commercial QCaaS and system sales model

source
stated

Achieve sustained profitability as first independent public quantum company

source
target: sustained profitability stated

Relationship graph · 204 connections

Competes with
63
Customer of
40
Developed by
23
Supplies to
11
listed on
10
Covered by
10
Employs
10
contracted by
5
headquartered in
Palo Alto

Via News coverage

Micron's Capex Nearly Doubled to $15.9 Billion as Analysts Cheer the AI Buildout, While European Exposure Runs Through Chips, Not Rules
October 9, 2026
Micron's Spending Tripled in Two Years as the AI Buildout Reached Memory Chips, While Weaker Corners of the Market Were Left Behind
October 1, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com